{
    "clinical_study": {
        "@rank": "144430", 
        "acronym": "HAIS-SE", 
        "arm_group": [
            {
                "arm_group_label": "Endovascular cooling", 
                "arm_group_type": "Active Comparator", 
                "description": "Endovascular cooling using the cooling device ZOLL Thermogard XP with ZOLL Quattro cooling catheter"
            }, 
            {
                "arm_group_label": "Surface cooling", 
                "arm_group_type": "Active Comparator", 
                "description": "Surface cooling using the cooling device BARD/Medivance Arctic Sun 5000 with BARD/Medivance Arctic Gel Pads"
            }, 
            {
                "arm_group_label": "Control group", 
                "arm_group_type": "No Intervention", 
                "description": "Best medical treatment following international stroke guidelines"
            }
        ], 
        "brief_summary": {
            "textblock": "HAIS-SE is evaluating for the first time ever in a randomized controlled trial efficacy,\n      tolerability, practicability and safety of endovascular versus surface cooling in awake\n      stroke patients."
        }, 
        "brief_title": "Hypothermia in Acute Ischemic Stroke - Surface Versus Endovascular Cooling (HAIS-SE)", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Ischemic Stroke", 
            "Thrombolysis", 
            "Hypothermia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypothermia", 
                "Ischemia", 
                "Stroke", 
                "Cerebral Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "Mild hypothermia improves outcome in patients with global cerebral ischemia after cardiac\n      arrest. Via animal models hypothermia has been identified as the most promising\n      neuroprotective therapy in focal cerebral ischemia as well. But the prove of clinical\n      benefit in patients with acute ischemic stroke is still missing: Most likely due to the\n      prolonged time window until hypothermia-induction (14 h) in previous studies. In addition,\n      feasibility of the method through which hypothermia is applied is crucial for a broad\n      implementation of hypothermia in stroke therapy. Surface versus endovascular cooling have\n      never been compared in a prospective trial in awake stroke patients.\n\n      HAIS-SE is evaluating for the first time ever in a randomized controlled trial efficacy,\n      tolerability, practicability and safety of endovascular versus surface cooling in awake\n      stroke patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ischemic stroke\n\n          -  Intravenous thrombolysis within 4.5h from symptom onset\n\n          -  Informed consent of the patient\n\n          -  NIHSS score \u2265 2 and \u2264 20\n\n          -  Age \u2265 18 and \u2264 90 years\n\n          -  Placement of cooling catheter / cooling pads within 6h from symptom onset\n\n        Exclusion Criteria:\n\n          -  (Expected) intubation (e.g. for interventional treatment)\n\n          -  Pregnancy\n\n          -  Body weight > 120kg\n\n          -  Body height < 150cm\n\n          -  Life-expectancy < 3 months\n\n          -  Fever > 38.5\u00b0C at screening\n\n          -  Known hematologic disease with increased risk of thrombosis (e.g. cryoglobulinemia,\n             cold agglutinins, sickle cell anemia)\n\n          -  Known vasospastic vascular disorder (e.g. Raynaud's phenomenon or thromboangiitis\n             obliterans)\n\n          -  Possible compression of the inferior vena cava (e.g. due to tumor) or vena cava\n             filter\n\n          -  Acute pulmonary embolism\n\n          -  Acute myocardial infarction\n\n          -  Severe cardiac insufficiency (NYHA \u2265 III)\n\n          -  Threatening ventricular dysrhythmia\n\n          -  QTc-interval > 450ms\n\n          -  Bradycardia < 50/min\n\n          -  Sick-Sinus-Syndrom\n\n          -  AV-block > I\u00b0\n\n          -  Severe infection with bacteremia or sepsis \u2264 72h\n\n          -  Severe renal (GFR < 30ml/min) or liver insufficiency (Child-Pugh C)\n\n          -  Myopathy\n\n          -  Known intolerance or allergy against acetaminophen, buspirone, clonidine, magnesium\n             sulphate or pethidine.\n\n          -  Treatment with MAO-inhibitors \u2264 14 days\n\n          -  Acute closed-angle glaucoma"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01665885", 
            "org_study_id": "HAIS-SE"
        }, 
        "intervention": [
            {
                "arm_group_label": "Endovascular cooling", 
                "description": "Induction of hypothermia with 1L cold crystalloid infusions (0,9%NaCl or Ringer's solution). Cooling catheter placement at the earliest 30min after end of thrombolysis.", 
                "intervention_name": "ZOLL Thermogard XP", 
                "intervention_type": "Device", 
                "other_name": [
                    "ZOLL Thermogard XP cooling device, ZOLL Circulation, Inc., USA", 
                    "ZOLL Quattro cooling catheter, ZOLL Circulation, Inc., USA"
                ]
            }, 
            {
                "arm_group_label": "Surface cooling", 
                "description": "Induction of hypothermia with 1L cold crystalloid infusions (0,9%NaCl or Ringer's solution) and simultaneous start of surface cooling.", 
                "intervention_name": "BARD/Medivance Arctic Sun 5000", 
                "intervention_type": "Device", 
                "other_name": [
                    "BARD/Medivance Arctic Sun 5000, C. R. Bard, Inc., USA", 
                    "BARD/Medivance Arctic Gel Pads, C. R. Bard, Inc., USA"
                ]
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "hypothermia", 
            "induction of hypothermia", 
            "non invasive cooling", 
            "external cooling", 
            "surface cooling", 
            "endovascular cooling", 
            "cooling catheter", 
            "stroke", 
            "shivering", 
            "neuro monitoring", 
            "coagulation"
        ], 
        "lastchanged_date": "June 21, 2013", 
        "link": {
            "description": "Heidelberg HYPOthermia 24/7 - Research group, information and contacts", 
            "url": "http://www.klinikum.uni-heidelberg.de/HYPO"
        }, 
        "location": {
            "contact": {
                "email": "sven.poli@med.uni-heidelberg.de", 
                "last_name": "Sven Poli, Dr. med.", 
                "phone": "0049 6221 56", 
                "phone_ext": "0"
            }, 
            "facility": {
                "address": {
                    "city": "Heidelberg", 
                    "country": "Germany", 
                    "zip": "69120"
                }, 
                "name": "Stroke Unit, Dept. of Neurology, University Hospital Heidelberg"
            }, 
            "investigator": [
                {
                    "last_name": "Sven Poli, Dr. med.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Christian Hametner, Dr. med.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jan C Purrucker, Dr. med.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Miriam Priglinger, Dr. med.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Maxim Bartz", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Marek Sykora, MD, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "HAIS-SE (Hypothermia in Acute Ischemic Stroke - Surface Versus Endovascular Cooling): A Randomized Trial Comparing Surface Versus Endovascular Cooling in Awake Stroke Patients Treated With Thrombolysis", 
        "overall_contact": {
            "email": "sven.poli@med.uni-heidelberg.de", 
            "last_name": "Sven Poli, Dr. med.", 
            "phone": "0049 6221 56", 
            "phone_ext": "0"
        }, 
        "overall_official": {
            "affiliation": "University Hospital Heidelberg", 
            "last_name": "Sven Poli, Dr. med.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Ethics Commission", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Primary endpoint: Time to primary target body core temperature (34\u00b0C) after hypothermia-induction.", 
            "measure": "Body core temperature", 
            "safety_issue": "No", 
            "time_frame": "0 to 48h"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01665885"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Hospital Heidelberg", 
            "investigator_full_name": "Dr. Sven Poli", 
            "investigator_title": "Dr. Sven Poli, Consultant Neurologist, Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Secondary efficacy outcome measures include the amount of patients reaching the primary target body core temperature (34\u00b0C), the time-frame until reaching 35\u00b0C body core temperature, temperature stability during maintenance and rewarming.", 
                "measure": "Efficacy", 
                "safety_issue": "Yes", 
                "time_frame": "0 to 48h"
            }, 
            {
                "description": "Tolerability outcome measures include a specific Hypothermia Participant Experience Questionnaire (HPEQ) and the Bedside Shivering Assessment Scale (BSAS) plus correlation with skin temperature, EMG and sNIRS.", 
                "measure": "Tolerability", 
                "safety_issue": "No", 
                "time_frame": "0 to 48h"
            }, 
            {
                "description": "Practicability outcome measures include a specific Hypothermia Nursing Staff Experience Questionnaire (HNEQ).", 
                "measure": "Practicability", 
                "safety_issue": "No", 
                "time_frame": "0 to 48h"
            }, 
            {
                "description": "Safety outcome measures include the analysis of (severe) adverse events (e.g. bleeding complications, pneumonia). 0 to 48h: Dose needed of anti-shivering medication, level of sedation (RASS, GCS and BIS), safety laboratory including specific coagulation parameters and monitoring of cerebral auto-regulation including cNIRS and BIS.", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "0 to d90"
            }
        ], 
        "source": "University Hospital Heidelberg", 
        "sponsors": {
            "collaborator": {
                "agency": "ZOLL Circulation, Inc., USA", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University Hospital Heidelberg", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}